12,372 trials
Healthy Volunteers (Meningococcal Infection)
Primary: Infants Groups 1 and 2: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at 30 Days Post Second…
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 12.22; 10.58 Months — p=0.144
Carcinoma, Non- Small Cell Lung
Primary: Disease-free Survival (DFS) — 3.9; 2.0 Months
Urinary Tract Infections · Spinal Cord Injuries · Spinal Cord Diseases
Primary: Number of Urinary Tract Infections (UTI) Over Time — 0.53; 0.09 UTI events per person months. — p=<0.0001
Uterine Leiomyoma · Uterine Fibroids
Primary: Percentage Of Participants Who Maintained MBL Volume Of <80 Milliliters (mL) At Week 76 During The Randomized Treatment Period — 78.43; 15.08 percentage of participants…
Primary Ovarian Insufficiency
Primary: Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) of the Lumbar Spine — 0.228; 0.673 Z-score
Meniere Disease
Primary: Number of Vertigo Episodes — 5.41; 5.03; 13.78 number of episodes — p=<0.001
Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 67; 122; 203; 4 Participants
Anesthesia; Adverse Effect
Primary: Pain Scores at 10-minute Intervals for the Initial Hour of Recovery — 0; 0; 1.0; 5.0 score on a scale — p=0.895
Atopic Dermatitis
Primary: Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 28.7 percentage of subjects
SARS-CoV-2
Primary: Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs) — 48; 41; 89 Participants
Angioedema
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During…
Psoriasis
Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Primary: Progression-Free Survival (PFS) — 4.04; 2.96 Months
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1second (ppFEV1) — 0.0; 0.2 percentage points — p=< 0.0001